Patten & Patten Inc. TN decreased its stake in Pfizer, Inc. (NYSE:PFE) by 12.9% during the second quarter, according to its most recent disclosure with the SEC. The firm owned 165,475 shares of the biopharmaceutical company’s stock after selling 24,568 shares during the period. Patten & Patten Inc. TN’s holdings in Pfizer were worth $5,558,000 as of its most recent filing with the SEC.
Several other large investors have also modified their holdings of the company. Perceptive Advisors LLC acquired a new stake in shares of Pfizer during the fourth quarter valued at approximately $1,786,000. Banco Santander S.A. acquired a new stake in shares of Pfizer during the fourth quarter valued at approximately $8,193,000. Focused Wealth Management Inc boosted its stake in shares of Pfizer by 1.1% in the fourth quarter. Focused Wealth Management Inc now owns 25,727 shares of the biopharmaceutical company’s stock valued at $836,000 after buying an additional 273 shares in the last quarter. Paulson & CO. Inc. acquired a new stake in shares of Pfizer during the fourth quarter valued at approximately $11,439,000. Finally, Ancora Advisors LLC boosted its stake in shares of Pfizer by 30.9% in the fourth quarter. Ancora Advisors LLC now owns 244,016 shares of the biopharmaceutical company’s stock valued at $7,926,000 after buying an additional 57,586 shares in the last quarter. Institutional investors own 70.10% of the company’s stock.
Shares of Pfizer, Inc. (NYSE:PFE) traded down 0.39% on Friday, reaching $33.29. 6,625,637 shares of the company’s stock were exchanged. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $35.38. The stock has a market cap of $198.67 billion, a P/E ratio of 24.35 and a beta of 1.00. The company’s 50 day moving average price is $33.43 and its 200-day moving average price is $33.30.
Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.11%. The business had revenue of $12.90 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter last year, the firm posted $0.64 EPS. Pfizer’s revenue was down 1.9% compared to the same quarter last year. Equities analysts forecast that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Investors of record on Friday, August 4th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 3.83%. The ex-dividend date of this dividend is Wednesday, August 2nd. Pfizer’s payout ratio is currently 94.12%.
ILLEGAL ACTIVITY NOTICE: “Patten & Patten Inc. TN Has $5.56 Million Stake in Pfizer, Inc. (PFE)” was published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.com-unik.info/2017/08/11/patten-patten-inc-tn-has-5-56-million-stake-in-pfizer-inc-pfe.html.
Several equities research analysts have recently commented on the stock. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. Jefferies Group LLC reiterated a “neutral” rating and set a $35.00 price target (up previously from $34.00) on shares of Pfizer in a research report on Thursday, April 13th. BMO Capital Markets reiterated a “hold” rating and set a $33.00 price target on shares of Pfizer in a research report on Thursday, April 27th. Sanford C. Bernstein reiterated a “buy” rating and set a $35.00 price target on shares of Pfizer in a research report on Monday, April 24th. Finally, Credit Suisse Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and lowered their price target for the stock from $38.00 to $36.00 in a research report on Thursday, July 20th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $37.77.
In other Pfizer news, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the transaction, the insider now directly owns 151,474 shares in the company, valued at approximately $5,074,379. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Ian C. Read sold 96,950 shares of the firm’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. Company insiders own 0.06% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.